The transaction
To be edited with the transaction overview.
Reasons to Vote FOR the Transaction
Has Aurora agreed to a transaction with Organigram?
Yes. Aurora has agreed to a proposed transaction under which Organigram would acquire Aurora, subject to shareholder, court, and regulatory approvals and other customary closing conditions.
A special committee of independent directors (the “Special Committee”) and the Aurora Board determined that the Transaction is in the best interests of Aurora, and the Aurora Board is recommending that Aurora shareholders vote in favour of the Transaction.
What am I entitled to receive under the transaction?
Aurora shareholders will have the option to elect to receive:
C$7.80 per Aurora Share in cash or 5.8626 common shares in the capital of Organigram per Aurora Share
OR
Combined consideration of C$3.75 per Aurora Share in cash plus 3.0431 Organigram Shares per Aurora Share held.
Proration:
Aurora shareholders electing to receive the Cash Consideration or the Share Consideration will be subject to proration as set out in the Arrangement Agreement so that the aggregate consideration will include no more than 205,816,172 Organigram Shares and no more than C$253,638,772 in cash.
Why is Aurora recommending this transaction?
The Board and Special Committee evaluated the transaction against the available alternatives, including Aurora continuing as a standalone company.
Following extensive review and due diligence, they concluded that the proposed transaction provides Aurora shareholders with compelling immediate value, meaningful choice in how they receive their consideration, and the opportunity for continued participation in the future growth and value creation of the combined company.
The combination brings together highly complementary Canadian global operators to create greater scale, broader capabilities, financial strength and international reach.
Did the Board and Special Committee consider alternatives?
Yes. The Transaction emerged from a robust strategic review process conducted by Aurora under the oversight of the Special Committee, with advice from independent legal and financial advisors. The review included an extensive market check and outreach to multiple parties.
Following that process, the Special Committee and Board determined that the Transaction is in the best interests of Aurora and believe it is superior to the Curaleaf Hostile Bid and the best actionable path forward to maximize value for Aurora shareholders.
Would Aurora shareholders own part of the combined company?
Shareholders who elect to receive organigram shares would participate in the combined company. Aurora shareholders are expected to collectively hold approximately 35% pro forma economic ownership and approximately 42% voting ownership on a fully diluted basis, giving them a meaningful opportunity to participate in the combined company’s future growth and value creation.
Who is Organigram?
Organigram Global Inc. is a cannabis company focused on producing high-quality cannabis for adult consumers and extending its global footprint. Listed on the NASDAQ Global Select Market and TSX, Organigram operates cultivation, processing and manufacturing facilities across Canada and, through its acquisition of Sanity Group, participates in the German medical cannabis market and other emerging markets within Europe.
How does this transaction compare with Curaleaf’s hostile bid offer?
Offer represents a 93% premium to Aurora’s Unaffected Share Price on August 10, 20261 and a 21% premium to the implied value of the unsolicited Curaleaf Hostile Bid as of November 2, 2026, unanimously rejected by Aurora’s Board of Directors.
The Aurora Board and the Special Committee continue to reiterate that Curaleaf’s unsolicited Hostile Bid is not in the best interests of the Company or the Aurora shareholders and unanimously recommends that the Aurora Shareholders REJECT the Hostile Bid by taking no action and NOT TENDERING their Aurora Shares.
Would shareholders have a vote?
Yes. Aurora shareholders will be asked to vote on the Transaction at a special meeting.
Full voting instructions and details will be provided in the joint information circular and related meeting materials.
The Aurora Board and Special Committee determined that the Transaction is in the best interests of Aurora, and recommend that Aurora shareholders vote in favour of the Transaction.
What is the recommendation of the board with regards to the CURALEAF offer?
The Aurora Special Committee and the Aurora Board continue to reiterate that the Hostile Bid from Curaleaf is not in the best interests of Aurora or its shareholders and unanimously recommend that shareholders REJECT the Hostile Bid by taking no action and DO NOT TENDER their Aurora Shares to the Hostile Bid.
I already tendered my shares. How do I withdraw them?
Contact Kingsdale Advisors for assistance with withdrawing or contact your broker to provide instructions to withdraw your tender instructions.
What action do I need to take now?
Until the joint management information circular is available, shareholders are not required to take any action in respect of the Transaction.